It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In multiple myeloma spatial differences in the subclonal architecture, molecular signatures and composition of the microenvironment remain poorly characterized. To address this shortcoming, we perform multi-region sequencing on paired random bone marrow and focal lesion samples from 17 newly diagnosed patients. Using single-cell RNA- and ATAC-seq we find a median of 6 tumor subclones per patient and unique subclones in focal lesions. Genetically identical subclones display different levels of spatial transcriptional plasticity, including nearly identical profiles and pronounced heterogeneity at different sites, which can include differential expression of immunotherapy targets, such as CD20 and CD38. Macrophages are significantly depleted in the microenvironment of focal lesions. We observe proportional changes in the T-cell repertoire but no site-specific expansion of T-cell clones in intramedullary lesions. In conclusion, our results demonstrate the relevance of considering spatial heterogeneity in multiple myeloma with potential implications for models of cell-cell interactions and disease progression.
The spatial architecture of multiple myeloma remains to be explored. Here, the authors perform bulk and single cell sequencing for samples from newly diagnosed patients and reveal gene signatures associated with focal lesions and spatial heterogeneity in the tumour microenvironment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Cancer Research Center (DKFZ), Clinical Cooperation Unit Molecular Hematology/Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
2 Heidelberg University Hospital, Department of Pathology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
3 University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
4 Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
5 Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany (GRID:grid.482664.a); German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Division of Stem Cells and Cancer, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
6 German Cancer Research Center (DKFZ) and BioQuant, Division of Chromatin Networks, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
7 German Cancer Research Center (DKFZ) and BioQuant, Single Cell Open Lab, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
8 Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany (GRID:grid.482664.a); German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Division of Stem Cells and Cancer, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
9 Institute of Health (BIH) at Charité—Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); Charité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
10 German Cancer Research Center (DKFZ), Division Computational Genomics and Systems Genetics, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Wellcome Trust Genome Campus, Wellcome Sanger Institute, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
11 Heidelberg University Hospital, Department of Orthopedic Surgery, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
12 Heidelberg University Hospital, Department of Radiology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
13 University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Cancer Research Center (DKFZ), Clinical Cooperation Unit Nuclear Medicine, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
14 University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
15 Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); National Center for Tumor Diseases (NCT), Heidelberg, Germany (GRID:grid.461742.2) (ISNI:0000 0000 8855 0365)
16 Roswell Park Comprehensive Cancer Center, Department of Medicine, Buffalo, USA (GRID:grid.240614.5) (ISNI:0000 0001 2181 8635)
17 University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637); University Hospital of Würzburg, Department of Internal Medicine 2, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891); University Hospital of Würzburg, Mildred Scheel Early Career Center (MSNZ), Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891)
18 Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany (GRID:grid.482664.a); Institute of Health (BIH) at Charité—Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); Charité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
19 Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Cancer Research Center (DKFZ), Clinical Cooperation Unit Molecular Hematology/Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)